Achieving hepatitis C cure may create false confidence about liver health, but new evidence reveals that metabolic dysfunction continues driving serious liver complications even after viral elimination. This finding challenges assumptions about post-cure liver safety and highlights an overlooked vulnerability in the growing population of hepatitis C survivors. Analysis of 1,185 patients who achieved hepatitis C eradication through direct-acting antiviral therapy demonstrated that each additional cardiometabolic risk factor increased the likelihood of liver-related events by 33 percent. Nearly half the patients developed metabolic dysfunction-associated steatotic liver disease, while prediabetes and diabetes emerged as independent predictors of future liver complications. The research employed the newly established steatotic liver disease classification system to categorize patients, revealing that metabolic factors—not residual viral activity—became the primary drivers of liver risk post-cure. This represents a paradigm shift in hepatitis C aftercare, suggesting that metabolic health management becomes crucial once antiviral treatment succeeds. The findings underscore a critical gap in current clinical practice, where patients may receive inadequate long-term monitoring after achieving sustained virologic response. For the estimated 4 million Americans cured of hepatitis C, this research indicates that traditional cardiovascular risk factors—obesity, insulin resistance, hypertension—directly translate into ongoing liver vulnerability. The 33 percent risk escalation per metabolic factor suggests that comprehensive metabolic screening and intervention should become standard components of post-hepatitis C care protocols, potentially preventing liver-related hospitalizations, cirrhosis progression, and hepatocellular carcinoma in this vulnerable population.